Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy

First-line immunotherapy in non-small-cell lung cancer largely improved patients’ survival. PD-L1 testing is required before immune checkpoint inhibitor initiation. However, this biomarker fails to accurately predict patients’ response. On the other hand, immunotherapy exposes patients to immune-rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Wlosik, J., Fattori, S., Rochigneux, P., Goncalves, A., Olive, D., Chretien, A. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974692/
https://www.ncbi.nlm.nih.gov/pubmed/36414693
http://dx.doi.org/10.1007/s00281-022-00973-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974692/
https://www.ncbi.nlm.nih.gov/pubmed/36414693
http://dx.doi.org/10.1007/s00281-022-00973-1

Ejemplares similares